Mohamad Mohty
Associate Editor at Blood Cancer Journal
Professor of Hematology; past-president of the EBMT; Chairman of the IACH; Editor in Chief: Bone Marrow Transplant; Clin Hematol Int.
Articles
-
1 month ago |
nature.com | Arnon Nagler |Nicolaus Kröger |Matthias Stelljes |Johan Maertens |Gesine Bug |Didier Blaise | +3 more
AbstractThe cytogenetic risk category retains a pivotal role in the prediction of prognosis in acute myeloid leukemia (AML) patients undergoing hematopoietic stem cell transplantation (HSCT), however, its impact on secondary AML (sAML) is less established. We assessed whether the ELN 2022 cytogenetic risk score predicts outcomes in sAML patients in remission undergoing HSCT from HLA-matched donors performed between 2010 and 2022.
-
1 month ago |
nature.com | Ali Bazarbachi |Didier Blaise |Eva Wagner-Drouet |Jakob Passweg |Ibrahim Yakoub-Agha |Peter Dreger | +3 more
AbstractAllogeneic hematopoietic cell transplantation remains an important curative treatment for patients with acute lymphoblastic leukemia (ALL). Over time, significant progress in transplant and post-transplant care has allowed the delivery of transplant to older patients. We assessed changes over time in characteristics and outcomes in patients ≥60 years with ALL using a dataset from the EBMT registry.
-
1 month ago |
nature.com | Aqeeb ur Rehman |Moazzam Shahzad |Faiz Anwer |Joseph McGuirk |Mohamad Mohty |Nausheen Ahmed | +1 more
AbstractMeasurable residual disease (MRD) testing is emerging as a crucial prognostic and treatment-guiding tool in multiple myeloma (MM). Despite its potential, routine clinical adoption remains inconsistent. This study aimed to explore oncologists’ perspectives on MRD testing and identify barriers and facilitators to its clinical integration. A cross-sectional, modified Delphi survey was conducted among hematologists and oncologists globally, and 115 responses were received.
-
Feb 11, 2025 |
nature.com | Jaime Sanz |Myriam Labopin |Jurjen Versluis |Didier Blaise |Lorenzo Lazzari |Juan Montoro | +7 more
AbstractWe retrospectively analyzed the impact of conditioning intensity on transplant outcomes according to their cytogenetic/molecular risk in a cohort of 1823 patients with acute myeloid leukemia (AML) and intermediate- or adverse-risk cytogenetics in first complete remission (CR1). These patients received their first hematopoietic stem cell transplantation (HSCT) using post-transplant cyclophosphamide (PTCy).
-
Feb 6, 2025 |
oncodaily.com | Mohamad Mohty
Mohamad Mohty, Chairman of the IACH, shared his recent article on X:Just published in Clinical Hematology International, the official peer-reviewed open access academic journal of The International Academy for Clinical Hematology (IACH). The journal welcomes your contributions: no submission fees or other hidden charges for academic authors. How to perform a high-quality peer reviewAuthors:
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 20K
- Tweets
- 37K
- DMs Open
- No
RT @TheIACH: 𝗚𝗲𝘁𝘁𝗶𝗻𝗴 𝗿𝗲𝗮𝗱𝘆 𝗳𝗼𝗿 #EHA2025 ? 𝘛𝘩𝘦 𝘐𝘯𝘵𝘦𝘳𝘯𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘈𝘤𝘢𝘥𝘦𝘮𝘺 𝘧𝘰𝘳 𝘊𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘏𝘦𝘮𝘢𝘵𝘰𝘭𝘰𝘨𝘺 (𝘐𝘈𝘊𝘏) 𝘸𝘪𝘭𝘭 𝘣𝘦 𝘢𝘤𝘵𝘪𝘷𝘦𝘭𝘺 𝘱𝘳𝘦𝘴𝘦𝘯𝘵 𝘪𝘯 𝘔𝘪𝘭𝘢𝘯 𝘸𝘪𝘵𝘩…
RT @TheIACH: 📢𝘑𝘰𝘪𝘯 𝘶𝘴 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘶𝘱𝘤𝘰𝘮𝘪𝘯𝘨 @TheIACH 𝘧𝘰𝘳 𝘕𝘶𝘳𝘴𝘦𝘴: 𝗣𝗿𝗼𝘃𝗶𝗱𝗶𝗻𝗴 𝗿𝗲𝗺𝗼𝘁𝗲 𝘀𝗽𝗲𝗰𝗶𝗮𝗹𝘁𝘆 𝗵𝗲𝗺𝗮𝘁𝗼𝗹𝗼𝗴𝘆 𝗰𝗮𝗿𝗲 𝘃𝗶𝗮 𝘁𝗲𝗹𝗲𝗵𝗲𝗮𝗹𝘁𝗵 🗓️𝘛𝘩𝘶𝘳𝘴𝘥𝘢𝘺, 𝘑𝘶𝘯𝘦 12…
RT @TheIACH: 𝗚𝗲𝘁𝘁𝗶𝗻𝗴 𝗿𝗲𝗮𝗱𝘆 𝗳𝗼𝗿 #EHA2025 ? 𝘛𝘩𝘦 𝘐𝘯𝘵𝘦𝘳𝘯𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘈𝘤𝘢𝘥𝘦𝘮𝘺 𝘧𝘰𝘳 𝘊𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘏𝘦𝘮𝘢𝘵𝘰𝘭𝘰𝘨𝘺 (𝘐𝘈𝘊𝘏) 𝘸𝘪𝘭𝘭 𝘣𝘦 𝘢𝘤𝘵𝘪𝘷𝘦𝘭𝘺 𝘱𝘳𝘦𝘴𝘦𝘯𝘵 𝘪𝘯 𝘔𝘪𝘭𝘢𝘯 𝘸𝘪𝘵𝘩…